Appendix 2: Selected Treatment Schedules for Neuro-Oncology


Chemotherapy Dose Route Schedule
Temozolomide, concomitant with radiotherapy  75 mg/m2  p.o. 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days 
Temozolomide, maintenance therapy  150 mg/m2 for cycle 1, 200 mg/m2 for subsequent cycles  p.o. 5/28 days, start 4 weeks after end of chemoradiotherapy, for up to 6 cycles 

1. Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987–996.

PCV (2,3)

Chemotherapy Dose Route Schedule
Procarbazine  60 mg/m2 p.o. Daily on Days 8–21 of every 6–8-week cycle 
CCNU (lomustine)  110 mg/m2  p.o. Day 1 of every 6–8-week cycle 
Vincristine  1.4 mg/m2 (maximal 2 mg)  i.v. Days 8 and 29 of every 6–8-week cycle 

2. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31:344–350. 3. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31:337–343.


Chemotherapy Dose Route Schedule
CCNU (lomustine)  110 mg/m2  p.o. Day 1 of every 6-week cycle 

4. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013; 31:3212–3218.

Last update: 18 September 2017